Interim evaluation of efficacy or futility in group‐sequential trials with multiple co‐primary endpoints

DOI10.1002/BIMJ.201600026zbMath1369.62288OpenAlexW2532695412WikidataQ39272947 ScholiaQ39272947MaRDI QIDQ5280188

Toshimitsu Hamasaki, Koko Asakura, Scott R. Evans

Publication date: 20 July 2017

Published in: Biometrical Journal (Search for Journal in Brave)

Full work available at URL: http://europepmc.org/articles/pmc6222168

zbMATH Keywords

futilitygroup sequential designmultiple endpointserror-spending methodnonbinding boundarytype I and type II error adjustments

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Optimal statistical designs (62K05) Sequential statistical analysis (62L10)

Uses Software

• QSIMVN

Cites Work

• Unnamed Item
• Unnamed Item
• Sample size determination in clinical trials with multiple endpoints
• Testing a Primary and a Secondary Endpoint in a Group Sequential Design
• Symmetric Group Sequential Test Designs
• Discrete Sequential Boundaries for Clinical Trials
• Design and Analysis of Group Sequential Clinical Trials with Multiple Primary Endpoints
• Stochastically curtailed tests in long–term clinical trials
• Group Sequential Tests for Bivariate Response: Interim Analyses of Clinical Trials with Both Efficacy and Safety Endpoints
• Closed Testing Procedures for Group Sequential Clinical Trials with Multiple Endpoints
• Guidelines for Monitoring Efficacy and Toxicity Responses in Clinical Trials
• Group-Sequential Clinical Trials with Multiple Co-Objectives

This page was built for publication: Interim evaluation of efficacy or futility in group‐sequential trials with multiple co‐primary endpoints